Lang, Joshua M <br/><br/>
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.  [electronic resource] 

 -  Cancer immunology, immunotherapy : CII  Oct 2011 
 - 1447-60 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1432-0851 
<br/><br/><label>Standard No.: </label>10.1007/s00262-011-1049-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Renal Cell--therapy<br/>Cell Separation<br/>Diphosphonates--therapeutic use<br/>Female<br/>Flow Cytometry<br/>Humans<br/>Imidazoles--therapeutic use<br/>Immunotherapy--methods<br/>Interleukin-2--therapeutic use<br/>Kidney Neoplasms--therapy<br/>Lymphocyte Activation--drug effects<br/>Male<br/>Middle Aged<br/>Pilot Projects<br/>Receptors, Antigen, T-Cell, gamma-delta--immunology<br/>T-Lymphocytes--immunology<br/>Zoledronic Acid